Table 3. Notch1 and Notch2 silencing decreases CLL cell viability independently of clinical characteristics and prognostic factors.
| Binet stages and prognostic factors | Number of patients | % Viability related to siCtrl (mean ± SD)a | |||
|---|---|---|---|---|---|
| siNotch1 | P | siNotch2 | P | ||
| Binet stage | |||||
| A | 5 | 70.5 ± 23.7 | 0.778 (A vs B) | 71.3 ± 20.4 | 0.594 (A vs B) |
| B | 8 | 73.8 ± 18.2 | 0.974 (B vs C) | 76.9 ± 16.1 | 0.924 (B vs C) |
| C | 9 | 74.1 ± 11.8 | 0.707 (C vs A) | 76.2 ± 12.2 | 0.580 (C vs A) |
| Previous treatmentb | |||||
| No | 7 | 68.1 ± 24.6 | 74.2 ± 20.0 | ||
| Yes | 15 | 75.5 ± 11.4 | 0.337 | 75.9 ± 13.1 | 0.814 |
| IgVH statusc | |||||
| Unm | 13 | 71.2 ± 14.1 | 73.5 ± 14.2 | ||
| Mut | 9 | 76.1 ± 20.0 | 0.505 | 78.0 ± 16.9 | 0.501 |
| ZAP70 expressiond | |||||
| Negative | 7 | 76.1 ± 19.2 | 75.0 ± 16.6 | ||
| Positive | 15 | 71.8 ± 15.6 | 0.579 | 75.4 ± 15.0 | 0.954 |
| CD38 expressionee | |||||
| Negative | 14 | 73.8 ± 14.2 | 74.7 ± 14.3 | ||
| Positive | 7 | 77.4 ± 15.8 | 0.599 | 80.4 ± 14.4 | 0.402 |
| NOTCH1 statusf | |||||
| Unm | 19 | 73.3 ± 17.7 | 75.6 ± 15.9 | ||
| Mut | 3 | 72.3 ± 6.2 | 0.925 | 73.6 ± 10.5 | 0.839 |
Mut, mutated; Unm, unmutated.
a
Percentage of viable cells determined by Annexin V/PI staining in siNotch1 or siNotch2 transfected CLL cells related to siCtrl cells as 100% viability.
b
Treated patients had not received treatment for at least 3 months before the study.
c
Mutated was defined as having a frequency of mutations >2% from germline VH.
d
Positivity refers to detection of >20% ZAP70+/CD19+.
e
Positivity refers to detection of >20% CD38+/CD19+.
f
c.7544_7545delCT in NOTCH1 exon 34.